Press Releases

March 7, 2025 Lupin Launches Rivaroxaban Tablets USP, 2.5mg in the United States

February 27, 2025 Lupin Secures a Place in the Prestigious S&P Global Sustainability Yearbook 2025

February 21, 2025 Lupin Receives EIR from U.S. FDA for its Somerset Manufacturing Facility

February 19, 2025 Lupin Receives “A-” Leadership Rating from CDP in Two Categories – Climate Change and Water Security

February 12, 2025 Lupin Q3 FY2025 Results

February 10, 2025 Lupin Receives Approval from U.S. FDA for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03%

February 10, 2025 Lupin and Natco Receive Approval from U.S. FDA for Bosentan Tablets for Oral Suspension

February 3, 2025 Lupin Receives Tentative Approval from U.S. FDA for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets

February 1, 2025 Lupin Announces Closure of Inspection by U.S. FDA at its Somerset Facility with No Observations